1
|
Shaqour B, Natsheh H, Kittana N, Jaradat N, Abualhasan M, Eid AM, Moqady R, AbuHijleh A, Abu Alsaleem S, Ratrout S, De Wever L, Vervaet C, Vanhoorne V. Modified Release 3D-Printed Capsules Containing a Ketoprofen Self-Nanoemulsifying System for Personalized Medical Application. ACS Biomater Sci Eng 2024; 10:3833-3841. [PMID: 38747490 DOI: 10.1021/acsbiomaterials.4c00476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2024]
Abstract
This study explores the realm of personalized medicine by investigating the utilization of 3D-printed dosage forms, specifically focusing on patient-specific enteric capsules designed for the modified release of ketoprofen, serving as a model drug. The research investigates two distinct scenarios: the modification of drug release from 3D-printed capsules crafted from hydroxypropyl methylcellulose phthalate:polyethylene glycol (HPMCP:PEG) and poly(vinyl alcohol) (PVA), tailored for pH sensitivity and delayed release modes, respectively. Additionally, a novel ketoprofen-loaded self-nanoemulsifying drug delivery system (SNEDDS) based on pomegranate seed oil (PSO) was developed, characterized, and employed as a fill material for the capsules. Through the preparation and characterization of the HPMCP:PEG based filament via the hot-melt extrusion method, the study thoroughly investigated its thermal and mechanical properties. Notably, the in vitro drug release analysis unveiled the intricate interplay between ketoprofen release, polymer type, and capsule thickness. Furthermore, the incorporation of ketoprofen into the SNEDDS exhibited an enhancement in its in vitro cylooxygenase-2 (COX-2) inhibitory activity. These findings collectively underscore the potential of 3D printing in shaping tailored drug delivery systems, thereby contributing significantly to the advancement of personalized medicine.
Collapse
Affiliation(s)
- Bahaa Shaqour
- Mechanical and Mechatronics Engineering Department, Faculty of Engineering and Information Technology, An-Najah National University, P.O. Box 7, Nablus P4110257, Palestine
- Medical and Health Sciences Research Center, An-Najah National University, P.O. Box 7, Nablus P4110257, Palestine
| | - Hiba Natsheh
- Medical and Health Sciences Research Center, An-Najah National University, P.O. Box 7, Nablus P4110257, Palestine
- Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus P4110257, Palestine
| | - Naim Kittana
- Medical and Health Sciences Research Center, An-Najah National University, P.O. Box 7, Nablus P4110257, Palestine
- Department of Biomedical Sciences, An-Najah National University, P.O. Box 7, Nablus P4110257, Palestine
| | - Nidal Jaradat
- Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus P4110257, Palestine
| | - Murad Abualhasan
- Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus P4110257, Palestine
| | - Ahmad M Eid
- Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus P4110257, Palestine
| | - Ruaa Moqady
- Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus P4110257, Palestine
| | - Aya AbuHijleh
- Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus P4110257, Palestine
| | - Saja Abu Alsaleem
- Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus P4110257, Palestine
| | - Shahd Ratrout
- Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus P4110257, Palestine
| | - Lotte De Wever
- Laboratory of Pharmaceutical Technology, Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
| | - Chris Vervaet
- Laboratory of Pharmaceutical Technology, Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
| | - Valérie Vanhoorne
- Laboratory of Pharmaceutical Technology, Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
| |
Collapse
|
2
|
Hawash M, Qneibi M, Natsheh H, Mohammed NH, Hamda LA, Kumar A, Olech B, Dominiak PM, Bdir S, Bdair M. Evaluating the Neuroprotective Potential of Novel Benzodioxole Derivatives in Parkinson's Disease via AMPA Receptor Modulation. ACS Chem Neurosci 2024; 15:2334-2349. [PMID: 38747411 DOI: 10.1021/acschemneuro.4c00163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2024] Open
Abstract
Parkinson's disease (PD) is a significant health issue because it gradually damages the nervous system. α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors play a significant role in the development of PD. The current investigation employed hybrid benzodioxole-propanamide (BDZ-P) compounds to get information on AMPA receptors, analyze their biochemical and biophysical properties, and assess their neuroprotective effects. Examining the biophysical characteristics of all the subunits of the AMPA receptor offers insights into the impact of BDZ-P on the desensitization and deactivation rate. It demonstrates a partial improvement in the locomotor capacities in a mouse model of Parkinson's disease. In addition, the in vivo experiment assessed the locomotor activity by utilizing the open-field test. Our findings demonstrated that BDZ-P7 stands out with its remarkable potency, inhibiting the GluA2 subunit nearly 8-fold with an IC50 of 3.03 μM, GluA1/2 by 7.5-fold with an IC50 of 3.14 μM, GluA2/3 by nearly 7-fold with an IC50 of 3.19 μM, and GluA1 by 6.5-fold with an IC50 of 3.2 μM, significantly impacting the desensitization and deactivation rate of the AMPA receptor. BDZ-P7 showed an in vivo impact of partially reinstating locomotor abilities in a mouse model of PD. The results above suggest that the BDZ-P7 compounds show great promise as top contenders for the development of novel neuroprotective therapies.
Collapse
Affiliation(s)
- Mohammed Hawash
- Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, P403, Nablus 00970, Palestine
| | - Mohammad Qneibi
- Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, An-Najah National University, P403, Nablus 00970, Palestine
| | - Hiba Natsheh
- Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, P403, Nablus 00970, Palestine
| | - Noor Haj Mohammed
- Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, An-Najah National University, P403, Nablus 00970, Palestine
| | - Lubaba Abu Hamda
- Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, An-Najah National University, P403, Nablus 00970, Palestine
| | - Anil Kumar
- Biological and Chemical Research Centre, Department of Chemistry, University of Warsaw, ul. Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Barbara Olech
- Biological and Chemical Research Centre, Department of Chemistry, University of Warsaw, ul. Żwirki i Wigury 101, 02-089 Warsaw, Poland
- Centre of New Technologies, University of Warsaw, ul. S. Banacha 2c, 02-097 Warsaw, Poland
| | - Paulina Maria Dominiak
- Biological and Chemical Research Centre, Department of Chemistry, University of Warsaw, ul. Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Sosana Bdir
- Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, An-Najah National University, P403, Nablus 00970, Palestine
| | - Mohammad Bdair
- Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, An-Najah National University, P403, Nablus 00970, Palestine
| |
Collapse
|
3
|
Messer L, Zoabi A, Yakobi R, Natsheh H, Touitou E, Margulis K. Evaluation of nasal delivery systems of olanzapine by desorption electrospray ionization mass spectrometry imaging. Int J Pharm 2024; 650:123664. [PMID: 38061498 DOI: 10.1016/j.ijpharm.2023.123664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2023] [Revised: 11/15/2023] [Accepted: 12/01/2023] [Indexed: 12/18/2023]
Abstract
Nose-to-brain delivery presents an attractive administration route for neuroactive drugs that suffer from compromised bioavailability or fail to pass the blood-brain barrier. However, the conventional gauge of effectiveness for intranasal delivery platforms primarily involves detecting the presence of the administered drug within the brain, with little insight into its precise localization within brain structures. This may undermine the therapeutic efficacy of drugs and hinder the design of systems that target specific brain regions. In this study, we designed two intranasal delivery systems for the antipsychotic drug, olanzapine, and evaluated its distribution in the rat brain following intranasal administration. The first evaluated system was an olanzapine-loaded microemulsion and the second one was nanoparticulate aqueous dispersion of olanzapine. Both systems exhibited characteristics that render them compatible for intranasal administration, and successfully delivered olanzapine to the brain. We further employed an ambient mass spectrometry imaging method, called desorption electrospray ionization mass spectrometry imaging, to visualize the signal intensity of olanzapine in different brain regions following the intranasal administration of these two systems. Substantial variations in the distribution patterns of olanzapine across various brain structures were revealed, potentially highlighting the importance of mass spectrometry imaging in designing and evaluating intranasal drug delivery platforms.
Collapse
Affiliation(s)
- Lihi Messer
- The Institute for Drug Research, the School of Pharmacy, the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112192, Israel
| | - Amani Zoabi
- The Institute for Drug Research, the School of Pharmacy, the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112192, Israel
| | - Ravit Yakobi
- The Institute for Drug Research, the School of Pharmacy, the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112192, Israel
| | - Hiba Natsheh
- The Institute for Drug Research, the School of Pharmacy, the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112192, Israel
| | - Elka Touitou
- The Institute for Drug Research, the School of Pharmacy, the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112192, Israel.
| | - Katherine Margulis
- The Institute for Drug Research, the School of Pharmacy, the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112192, Israel.
| |
Collapse
|
4
|
Moeini R, Shirafkan H, Gorji N. Pomegranate effects on the health aspects of women during peri- and postmenopause: A systematic review and meta-analysis. Phytother Res 2024; 38:368-383. [PMID: 37929766 DOI: 10.1002/ptr.8036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2023] [Revised: 08/05/2023] [Accepted: 09/29/2023] [Indexed: 11/07/2023]
Abstract
Pomegranate is widely used to preserve human health and help prevent many kinds of diseases. This study aims to review and assess the effects of pomegranate on women's health during and after menopause. PubMed, Web of science, Cochrane, Scopus, and Google Scholar were searched up to the end of 2022 with no language or study type restriction. All types of clinical research studies (randomized clinical trial [RCT], pre-post, case report, and case series) were included. The Cochrane RoB 2.0 tool was used for quality assessment of RCTs. A summary of intervention's effects for each study was provided by calculating standardized mean differences and accompanying 95% confidence interval using random effect model. Weighted mean differences and heterogeneity between studies were assessed using Hedges's method and Cochran's Q test, respectively. Pomegranate can significantly improve hot flashes severity and menopause symptoms and decrease FSH. It significantly improves high-density lipoprotein but not low-density lipoprotein, body mass index, and weight. Most of our results are inconclusive, and the small sample sizes and the lack of blinding and randomization have led to an increased risk of bias. Pomegranate can decrease menopause symptoms, but more well-designed studies, with bigger sample sizes are needed to establish its other clinical benefits for menopausal women.
Collapse
Affiliation(s)
- Reihaneh Moeini
- Traditional Medicine and History of Medical Sciences Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
| | - Hoda Shirafkan
- Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
| | - Narjes Gorji
- Traditional Medicine and History of Medical Sciences Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
| |
Collapse
|
5
|
Sousa F. Brain-Targeted Drug Delivery. Pharmaceutics 2022; 14:pharmaceutics14091835. [PMID: 36145583 PMCID: PMC9500829 DOI: 10.3390/pharmaceutics14091835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Accepted: 08/30/2022] [Indexed: 12/05/2022] Open
Affiliation(s)
- Flávia Sousa
- Adolphe Merkle Institute, University of Fribourg, Chemin des Verdiers 4, 1700 Fribourg, Switzerland
| |
Collapse
|